Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk

Both the low animal cell density of bioreactors and their ability to post-translationally process recombinant factor IX (rFIX) limit hemophilia B therapy to <20% of the world’s population. We used transgenic pigs to make rFIX in milk at about 3,000-fold higher output than provided by industrial b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jianguo, Xu, Weijie, Ross, Jason W., Walters, Eric M., Butler, Stephen P., Whyte, Jeff J., Kelso, Lindsey, Fatemi, Mostafa, Vanderslice, Nicholas C., Giroux, Keith, Spate, Lee D., Samuel, Melissa S., Murphy, Cliff N., Wells, Kevin D., Masiello, Nick C., Prather, Randall S., Velander, William H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585688/
https://www.ncbi.nlm.nih.gov/pubmed/26387706
http://dx.doi.org/10.1038/srep14176

Ejemplares similares

Ejemplares similares